Centene Boosts Specialty Drug Expertise With Pair of Deals
Centene Corp. celebrated the end of 2020 by closing on its acquisition of specialty pharmacy PANTHERx Rare, LLC on Dec. 30, then started 2021 with an agreement to acquire Magellan Health, Inc. The deals will strengthen Centene’s expertise in the specialty pharmacy space, particularly in the burgeoning orphan drug space by bringing onboard PANTHERx, an experienced company that’s shown remarkable growth over the past 10 years.
Centene and PANTHERx did not disclose terms of the deal, which was unveiled Dec. 15.
Related Posts

January 12
More Complex Specialty Drug Management, Pandemic Pressures and Inflation Reduction Act Were Some 2022 Trends
READ MORE
January 12
New FDA Approvals: FDA Gives Accelerated Approval to Mirati’s Krazati
READ MORE
January 12